CR Group L.P. - 12 Apr 2024 Form 4 Insider Report for T2 Biosystems, Inc. (TTOO)

Role
10%+ Owner
Signature
/s/ Nathan D. Hukill, authorized signatory for CR Group LP, CRG Partners III LP, CRG Partners III - Parallel Fund (A) LP, CRG Partners III (Cayman) Unlev AIV I LP, CRG Partners III (Cayman) Lev AIV I LP, and CRG Partners III - Parallel Fund B (Cayman) LP
Issuer symbol
TTOO
Transactions as of
12 Apr 2024
Net transactions value
$0
Form type
4
Filing time
16 Apr 2024, 20:35:46 UTC
Previous filing
16 Feb 2024
Next filing
07 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TTOO Common Stock Award +682,036 682,036 12 Apr 2024 By CRG Partners III L.P. F1, F2
transaction TTOO Common Stock Award +424,716 424,716 12 Apr 2024 By CRG Partners III - Parallel Fund (A) L.P. F1, F2
transaction TTOO Common Stock Award +136,409 136,409 12 Apr 2024 By CRG Partners III (Cayman) Unlev AIV I L.P. F1, F2
transaction TTOO Common Stock Award +1,647,315 +490% 1,983,262 12 Apr 2024 By CRG Partners III (Cayman) Lev AIV I L.P. F1, F2
transaction TTOO Common Stock Award +390,142 +80% 878,415 12 Apr 2024 By CRG Partners III - Parallel Fund B (Cayman) L.P. F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TTOO Series A Convertible Preferred Stock Award $0 +17,160 +158% $0.000000 28,036 12 Apr 2024 Common Stock 1,716,048 By CRG Partners III - Parallel Fund B (Cayman) L.P. F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to that certain Securities Purchase Agreement, dated February 15, 2024, by and among the Company, CRG Partners III L.P., CRG Partners III - Parallel Fund (A) L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III (Cayman) Lev AIV I L.P. and CRG Partners III - Parallel Fund B (Cayman) L.P. (collectively, the "CRG Entities"), the CRG Entities received these shares of common stock in exchange for the CRG Entities surrendering for cancellation of certain outstanding debt.
F2 CR Group L.P. may be deemed to beneficially own these shares by virtue of its position as the investment manager for the CRG Entities.
F3 Each share of Series A Convertible Preferred Stock (the "Series A Preferred") converts into 100 shares of the Company's common stock at the holder's election, subject to beneficial ownership limitations, including that a holder of Series A Preferred is prohibited from converting such shares into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 49.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. As a result of the 49.99% beneficial ownership limitation, as of April 12, 2024, the Series A Preferred held by the reporting persons can be converted into a maximum of 1,173,600 shares of common stock in the aggregate. The shares of Series A Preferred have no expiration date.
F4 The preferred stock has no expiration date.